Business Wire (Tue, 5:57PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,329 people get NPSP articles and Market Currents by email alert.
Get email alerts on NPSP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Mon, 4:21PM)
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
-
-
-
-
-
-
Business Wire (Mar 5, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Current Prime Pharma Entries In Anticipation Of Prime Time ExitsChemistfrog • Tue, Nov 6, 2012 -
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
-
NPS Pharmaceuticals' CEO Discusses Gattex Update (Transcript)Wed, Oct 17, 2012 • 1 Comment
-
NPS Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
NPS Pharmaceuticals Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
NPS Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Business Wire (Tue, 5:57PM)
-
Business Wire (Mon, 4:21PM)
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 5, 2013)
-
at CNBC.com (Jan 7, 2013)
-
Business Wire (Jan 3, 2013)
NPSP vs. ETF Alternatives
Company Description
Currently, there's no company description for NPSP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, November 9, 2012, 8:07 AM NPS Pharmaceuticals (NPSP): Q3 EPS of -$0.04 beats by $0.12. Revenue of $27M (+9.8% Y/Y) misses by $1.2M. (PR) Comment! [Earnings, Healthcare]
- Friday, November 9, 2012, 12:05 AM Notable earnings before Friday’s open: AEE, BAM, COV, FWLT, JCP, LNT, MEA, MHR, MTG, NPSP, VTG, WCRX, XTEX Comment! [Earnings]
- Thursday, November 8, 2012, 5:30 PM Notable earnings before Friday’s open: AEE, BAM, COV, FWLT, JCP, LNT, MEA, MHR, MTG, NPSP, VTG, WCRX, XTEX Comment! [Earnings]
-
Friday, October 12, 2012, 12:45 PM
Midday top 10 gainers: NINE +62%. CRMB +16%. NPSP +15%. AEGR +13%. GLUU +12%. LXRX +11%. TSON +11%. BIOF +10%. EMAN +10%. BSDM +9%.
Top 10 Losers: AEZS -24%. OCZ -17%. TZOO -14%. PURE -11%. INVE -11%. AMD -10%. LQDT -10%. CCCL -9%. INFY -9%. Comment! [On the Move] - Friday, October 12, 2012, 12:37 PM NPS Pharmaceuticals (NPSP 14.3%) pops today after it says the FDA has released the briefing documents ahead of its October 16 Advisory Committee meeting for NPSP's experimental drug Gattex, which is being developed for the treatment of adults with short bowel syndrome. The overall comments appear to be positive, with no serious safety issues raised. The advisers also said access to the drug should not be restricted, nor will it require additional elements to assure it's safe use. Comment! [Healthcare, On the Move]
-
Friday, October 12, 2012, 9:10 AM
Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.
Losers: AEZS -24%. AMD -11%. INFY -7%. 1 Comment [On the Move] - Wednesday, August 1, 2012, 6:54 PM NPS Pharmaceuticals (NPSP): Q2 EPS of $0.08 beats by $0.17. (PR) Comment! [Earnings, Healthcare]
-
Friday, June 22, 2012, 9:10 AM
Premarket gainers: HNR +82%. ALXA +19%. NPSP +9%.
Losers: PLX -12%. R -10%. 2 Comments [On the Move] - Friday, June 22, 2012, 9:03 AM NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK) say a European panel recommended their Revestive drug receive marketing approval as a once-daily treatment for adults with short bowel syndrome. Comment! [Healthcare, On the Move]
- Thursday, May 3, 2012, 8:21 PM NPS Pharmaceuticals (NPSP): Q1 EPS of -$0.12 misses by $0.01. Revenue of $22.2M (-3% Y/Y) misses by $1.7M. (PR) 2 Comments [Earnings, Healthcare]
- Wednesday, February 15, 2012, 5:15 PM NPS Pharmaceuticals (NPSP): Q4 EPS of -$0.10 beats by $0.01. Revenue of $26.3M (+9.6% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Tuesday, February 7, 2012, 9:05 AM Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015. Comment! [Healthcare, Quick Ideas]
- Tuesday, January 31, 2012, 9:46 AM NPS Pharmaceuticals (NPSP +1.8%) trades higher after the FDA accepts its Gattex drug application for review. Slicing through the firm's statement a bit - it appears that it didn't land a coveted "priority" review from the FDA. Comment! [Healthcare, On the Move]
- Friday, December 2, 2011, 12:10 PM NPS Pharmaceuticals (NPSP +5.4%) clocks a gain a day after announcing it completed its submission to the FDA for its experimental Gattex drug - a hopeful sign which follows the firm reporting "adverse events" in October with trials. Comment! [Healthcare, On the Move]
- Wednesday, November 9, 2011, 1:47 PM NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at treating hypoparathyroidism will be successful following positive clinical testing of the treatment, helping offset problems with its experimental Gattex drug. Stifel Nicolaus expects both drugs to eventually win US approval, setting a price target of $11 on shares. Leerink Swann aims even higher with a $14-$16 price target - repping a tripling of the stock's current value. Comment! [Healthcare]
- Monday, November 7, 2011, 1:44 PM NPS Pharmaceuticals (NPSP -3.7%) gives back all its premarket gains and more, despite the postive Phase 3 results for its hypoparathyroid treatment earlier today. The company has been on a steady downtrend for most of this year, losing nearly 50% since hitting a 52-week high in May. 1 Comment [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/OjPhJ3 $NPSP upcoming FDA approval on September 30th. Its time to a look at this stock. - View all 0 replies
-
- View all 0 replies
-
Bryce Istvan
NPSP down on failed AMGN "Evolve" trial. Means no expanded indication for Sensipar and no extra royalties http://bit.ly/MiIJsj - View all 0 replies
-
- View all 0 replies
-
Robert Weinstein
Looking to short NPSP for an overnight. Price up over 30% and I don't feel possible drug earnings don't justify it. - View all 0 replies
-
candlestickpicks
$NPSP completed a Morning Star candlestick pattern on 11/18/2010. Look for an upward price movement on 11/19/2010 - View all 0 replies
LATEST REPLIES